doxazosin has been researched along with dutasteride in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brown, GA; Sussman, DO | 1 |
| Barnett, G; Brown, CT; Ellis, BW; Emberton, M; Ryan, M; Watson, V | 1 |
| O'Leary, MP | 1 |
| Gratzke, C; Reich, O; Schlenker, B; Seitz, M; Stief, CG; Weidlich, P | 1 |
| Adomat, H; Elterman, DS; Fleshner, N; Guns, E; Hersey, K; Lawrentschuk, N; Wood, CA | 1 |
| Kuo, HC; Liao, CH; Lin, VC; Wang, CC | 1 |
| Kuo, HC; Liao, CH; Lin, VC | 1 |
| Zisman, A | 1 |
| Carini, M; Corona, G; Ficarra, V; Gacci, M; Maggi, M; Novara, G; Sebastianelli, A; Serni, S; Shariat, SF; Zattoni, F | 1 |
| Arenas-Duque, A; Garcia-Perdomo, HA; Guevara-Cuellar, CA; Parody-Rúa, E | 1 |
4 review(s) available for doxazosin and dutasteride
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Comorbidity; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Global Health; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome | 2006 |
[Benign prostatic hyperplasia: medical therapy].
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Disease Progression; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Muscarinic Antagonists; Phosphodiesterase Inhibitors; Phytotherapy; Plant Extracts; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2007 |
Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Doxazosin; Dutasteride; Ejaculation; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Sexual Dysfunction, Physiological; Sulfonamides; Tamsulosin; Urological Agents | 2014 |
1 trial(s) available for doxazosin and dutasteride
| Article | Year |
|---|---|
Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Azasteroids; Disease Progression; Doxazosin; Drug Therapy, Combination; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Prospective Studies; Prostatic Hyperplasia; Time Factors | 2014 |
7 other study(ies) available for doxazosin and dutasteride
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
A current review of medical therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Urination Disorders | 2004 |
Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Azasteroids; Doxazosin; Dutasteride; Humans; Male; Middle Aged; Patient Satisfaction; Prostatic Hyperplasia; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Urination Disorders | 2004 |
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Azasteroids; Capsules; Cholestenone 5 alpha-Reductase; Chromatography, High Pressure Liquid; Doxazosin; Drug Contamination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tablets; Tamsulosin | 2010 |
5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Biopsy; Chi-Square Distribution; Disease Progression; Doxazosin; Drug Therapy, Combination; Dutasteride; Humans; Male; Middle Aged; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Quality of Life; Taiwan; Treatment Outcome | 2015 |
Editorial comment.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Doxazosin; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia | 2014 |
Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Adult; Colombia; Cost-Benefit Analysis; Doxazosin; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia | 2018 |